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Introduction: Autologous hematopoietic stem cell transplantation is a conduct used to treat
some hematologic diseases and to consolidate the treatment of others. In the ﬁeld of nurs-
ing, the few published scientiﬁc studies on nursing care and early hospital discharge of
transplant patients are deﬁcient. Knowledge about the diseases treated using hematopoi-
etic stem cell transplantation, providing guidance to patients and caregivers and patient
monitoring are important nursing activities in this process. Guidance may contribute to
long-term goals through patients’ short-term needs.
Aim: To analyze the results of early hospital discharge on the treatment of patients submit-
ted to autologous transplantation and the inﬂuence of nursing care on this conduct.
Methods: Aretrospective, quantitative, descriptive and transversal studywas conducted. The
hospital records of 112 consecutive patients submitted to autologous transplantation in the
period from January to December 2009 were revisited. Of these, 12 patients, who remained
in hospital for more than ten days after transplantation, were excluded from the study.
Results: The medical records of 100 patients with a median age of 48.5 years (19–69 years)
were analyzed. All patients were mobilized and hematopoietic stem cells were collectedby leukapheresis. The most common conditioning regimes were BU12Mel100 and BEAM400. Toxicity during conditioning was easily managed in the outpatient clinic. Gastroin-
testinal toxicity, mostly Grades I and II, was seen in 69% of the patients, 62% of patients had
diarrhea, 61% of the patients had nausea and vomiting and 58%had Grade I and IImucositis.
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Ten patients required hospitalization due to the conditioning regimen. Febrile neutropenia
was seen in 58% of patients. Two patients died before Day +60 due to infections, one with
aplasia. The median times to granulocyte and platelet engraftment were 12 days and 15
days, respectively, with median red blood cell and platelet transfusions until discharge of
three and four units, respectively. Twenty-three patients required rehospitalization before
being discharged from the outpatient clinic.
Conclusion: The median time to granulocyte engraftment was 12 days and during the aplasia
phase few patients were hospitalized or suffered infections. The toxicity of the conditioning
was the leading cause of rehospitalization. The nursing staff participated by providing guid-
ance to patients and during the mobilization, transplant and outpatient follow-up phases,
thus helping to successfully manage toxicity.
© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
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utologous hematopoietic stem cell transplantation (aHSCT)
s a conduct used to treat some hematologic diseases and to
onsolidate the treatment of other diseases.1–3 The increased
emand for transplants has required the creation of some
odels. Early hospital discharge is a strategy in which the
atient leaves the hospital after the conditioning regimen
nd hematopoietic stem cell (HSC) infusion with treatment
eing continued under outpatient conditions.2,4 Although
utpatient hematopoietic stem cell transplantation (HSCT)
odels are well deﬁned, there is a paucity of studies and
cientiﬁc publications. In the ﬁeld of nursing, the limited
umber of scientiﬁc studies related to nursing care and
arly hospital discharge of transplant patients are deﬁ-
ient. Knowledge about the diseases treated using HSCT,
roviding guidance to patients and caregivers and patient
onitoring are important nursing activities in this process.
he guidance provided to patients may contribute to long-
erm goals through their short-term needs. The objectives
f this study were to analyze the results of early hospi-
al discharge as a viable alternative in the treatment of
atients submitted to aHSCT and the inﬂuence of nursing
are on this conduct. The patient compliance contributes to
he achievement of goals in the long term by the need for
hort-term.5–7
ethods
his was a retrospective, quantitative, descriptive and
ransversal study. The records of 112 consecutive patients
ubmitted to aHSCT in the Hospital das Clínicas da Facul-
ade de Medicina da Universidade de São Paulo (HC-FMUSP)
uring the period from January 5, 2009 to December 7, 2009
ere evaluated for inclusion in this study. The inclusion crite-
ia were patients who were discharged from hospital within
he ﬁrst ten days after HSCT (D+10), age between 18 and 70
ears and continued to be treated in the outpatient clinic until
ischarge. Of the 112 patients considered for this study, 100
et the inclusion criteria: 45 patients with multiple myeloma
MM), 21 patients with Hodgkin’s lymphoma (HL), 25 patients
ith non-Hodgkin lymphoma (NHL) and nine patients with adiagnosis of acute myelogenous leukemia (AML). The 12
remaining patients were not discharged from hospital before
D+10 andwere therefore excluded. The data collected covered
the procedure from the mobilization phase until outpatient
discharge.
Conditioning regimen-related toxicities were graded using
the World Health Organization toxicity scale adapted for the
service by Nicolau.8 The occurrence of infections was evalu-
ated from the admission of the patient in the outpatient clinic
until D+30. Some protocols were followed from admission to
outpatient care, including the collection of samples for cultur-
ing in order to identify infections early. Patients with positive
results were treated.
Statistical analysis
Descriptive statistics were employed to analyze the variables
using absolute numbers, means and percentages of each of
the proposed outcomes.
Results
The characteristics of enrolled patients and the results of
the HSCT are shown in Table 1. The mobilization of HSC to
the peripheral blood was achieved using cyclophosphamide
(120mg/kg weight) and granulocyte colony-stimulating fac-
tor (G-CSF – 10 to 20mcg/kg weight) in 85 (85%) patients.
G-CSF alone was used for mobilization in 10 patients,
eight of whom had multiple myeloma in complete response
and two had acute myelogenous leukemia. A regimen of
cyclophosphamide (120mg/kg weight), gemcitabine (2 g/m2)
and G-CSF (10–20mcg/kg weight) was used for ﬁve patients,
three patients with Hodgkin’s lymphoma and two with non-
Hodgkin lymphoma. All patients included in this study
collected the HSC through a central venous catheter (CVC)
by leukapheresis until the required number of CD34+ cells for
HSCT was obtained.
In this sample 9/36 (25%) episodes of hospitalization,
resulting from the toxicity of the conditioning regimen were
observed. Grade II and III diarrhea was the most frequent
symptom of toxicity in 27/36 (75%) patients.
Febrile neutropenia was seen in 58% of the patients before
bone marrow engraftment. Of the 100 patients analyzed, 11
266 rev bras hematol hemoter.
Table 1 – Characterization of the patients and results of
hematopoietic stem cell transplantation (n=100).
Characterization of the patients
Gender – n (%)
Male 49 (49)
Female 51 (51)
Age: median (range) – years 48.5 (19–69)
Racial background
White 63 (63)
Mulatto 23 (23)
Black 14 (14)
Underlying disease – n (%)
Multiple myeloma 45 (45)
Hodgkin’s lymphoma 25 (25)
Non-Hodgkin’s lymphoma 21 (21)
Acute myeloid leukemia 9 (9)
Mobilization – n (%)
Median peripheral CD34+ cells (cell/mm3)
(range)
23.75 (6.3–709.1)
Median days of mobilization (range) 13 (3–34)
Median CD34+ cells infused (×106) (range) 4.74 (2.3–30.1)
Toxicity of conditioning regimen
Mucositis – n (%)
Grade 0 31 (31)
Grade 1–2 58 (58)
Grade 3–4 11 (11)
Nausea/vomiting – n (%)
Grade 0 16 (16)
Grade 1 62 (62)
Grade 2 14 (14)
Grade 3 8 (8)
Diarrhea – n (%)
Grade 0 25 (25)
Grade 1 14 (14)
Grade 2 31 (31)
Grade 3 30 (30)
Days after HSCT to hospital discharge – n (%)
D+1 59 (59)
D+2 18 (18)
D+3 9 (9)
D+4 6 (6)
D+5 2 (2)
D+6 4 (4)
D+9 2 (2)
Engraftment
Granulocytes: median days 12
Platelets: median days 15patients had positive cultures before D+30, seven of whom
(7/11; 63.6%) were infected during the period of bone mar-
row aplasia. One patient presented blood cultures with two
different microorganisms.
Four patients died in the study period before D+100, two
due to septic shock, one due to viral pneumonia and the other
due to disease relapse.
The median length of stay of patients in the service was 55
days, ranging from 26 to 114 days.2014;36(4):264–268
Discussion
This retrospective analysis was carried out with consecutive
patients from a single transplant center. The objective was to
answer questions related to the safety and feasibility of early
hospital discharge after aHSCT.
The reduction in the length of hospital stay of patients
with hematologic diseases with early hospital discharge to
outpatient facilities has been a trend in recent years.9 Early
discharge allows greater agility in the number of patients
treated thereby reducing the waiting time for HSCT.
The nursing staff has an important role in the care of
patients submitted to HSCT because, regardless of the treat-
ment phase, nurses need to establish communication links
with patients and their caregivers and through interpersonal
relationships gain their trust. With good communications, the
professional can assist patients to conceptualize their prob-
lems and address them, showing them their participation in
the experience, in addition to helping them ﬁnd new behav-
ior patterns.10 Members of the nursing staff must constantly
seek to provide assistance to ensure the quality and safety of
treatment, provide appropriate guidance, identify signs and
symptoms with prompt intervention and offer measures of
comfort.
The proposal to examine some aspects of mobilization
along with the results of the HSCT allowed an investigation
of factors to see whether there is any relationship between
the phases before and after transplantation by establishing a
relationship of the results ofmobilization andHSCTwith early
hospital discharge. Based on the literature and in acccordance
with our results the possible implications for nursing can be
assessed which is important as, according to Mank et al.,9
there has been a decrease in the length of hospital stay of
patients with hematologic diseases in recent years due to the
ease of treatment in the outpatient regimen.9
Some factors such as age, the type and dose of growth
factor (single daily dose or fractionated) and chemother-
apy/radiotherapy towhich patientswere previously submitted
may interfere in the mobilization of HSC.3,11,12 It is well
known that patients who receive alkylating agents in dis-
ease treatment schemes can present major difﬁculties and
mobilization can even be unsuccessful.3 In this study, the
results of the HSCT did not signiﬁcantly differ with respect
to age, gender or race. Mobilization was carried out using
chemotherapy and G-CSF (90% of patients) or just G-CSF
(10%). StimulationusingG-CSF can cause someadverse effects
including bone pain, myalgia, fever, headache and nausea
but these are well tolerated by patients. Secondary compli-
cations, such as the splenic rupture and respiratory distress
syndrome, rarely occur with the use of G-CSF.3,13 At the
mobilization stage, by using their experience and scientiﬁc
knowledge, the nursing staff should design a plan of preven-
tative care and interventions in regard to possible adverse
effects. Independent of the mobilization regimen in this
study, HSC collections never failed. By consensus, an amount
of 2.0×106 CD34+ cells/kg weight produces good neutrophil
and platelet engraftment within approximately 14 days after
HSCT.3 In some centers, 5.0×106 CD34+ cells/kg weight is con-
sidered the optimal value because it decreases the time to
er. 20
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transplantation for patients with multiple myeloma. Hematol
J. 2004;5:222–6.
3. Rosenbeck LL, Srivastava S, Kiel PJ. Peripheral blood stem cellrev bras hematol hemot
ematologic engraftment.13–15 Our ﬁndingswere quite consis-
ent with the literature, where the median CD34+ cells from
atients’ collections was 4.74×106 kg−1 weight, the median
ime to neutrophil engraftment was 12 days, and the median
ime to platelet engraftment was 15 days. During this phase,
t is clear that the nursing staff actively participates in the
recise veriﬁcation of the patient’s height and weight, pro-
ides explanations about the apheresis collection procedure
nd ﬂuid intake, takes care of the venous access site, moni-
ors laboratory tests as well as informing about the number of
ells collected and providing support to continue the stimula-
ion regimen upon medical prescription when more than one
ollection is necessary.
After the HSC infusion procedure, patients are discharged
rom hospital to continue treatment in the outpatient clinic.
ue to the high doses of chemotherapy, patients present dif-
erent degrees of symptoms that may or may not allow them
o continue in the outpatient clinic. Gastrointestinalmucositis
s generally the most important non-hematologic toxicity16;
t was present in 69% of the patients in this study, mostly
rades I to II. These cases were easily managed in the outpa-
ient clinic however one patient required hospitalization due
o Grade IV mucositis. Sixty-two percent of patients had Grade
and II diarrhea and 61% had nausea and vomiting. Fifty-eight
ercent of patients presented Grade I and II mucositis.
In a study conducted of 297 consecutive adult patientswith
M, NHL, HL and AML at different stages, types, responses
nd number of prior treatments, who were submitted to
HSCT, one of the main results, neutropenic colitis, was more
ommon in patients with NHL who had received the BEAM
onditioning regimen, but with modiﬁed doses of cytarabine
nd etoposide. It is well known that both agents induce dam-
ge to the gastrointestinal tract lining and that the use of
ytarabine has been associated with neutropenic colitis.17 Our
ata show that of the 46 patients who were submitted to the
EAM400 or BEAM schemes, 31 (67.39%) presented with diar-
hea.
The median time to hospital discharge of patients was
ne day after the HSC infusion procedure. At this stage of
he conditioning regimen, nurses must inform patients and
heir caregivers about adverse effects, including pancytope-
ia with the frequent changes of the mucosa and about
ain control.18 They must also assess the fatigue, anxiety,
nsomnia, poor appetite, mucositis, nausea and vomiting of
he patients. These are among the most common symptoms
eported during HSCT.19 Nurses are essential in the contin-
ous assessment of symptoms and are also responsible for
vidence-based nursing interventions.18 Symptoms can affect
he quality of life of patients20,21 and, therefore, in the con-
ext of early hospital discharge the nurse should pay attention
o patient complaints, trying to minimize the possibility of
vents outside the hospital, counseling them on how to iden-
ify possible changes and the necessity to seek professional
ssistance when changes do occur. The detection and rating
f toxicities should be accurate, leading to early intervention
n cases of worsening even possibly the need of hospitaliza-
ion. Re-admission to hospital due to conditioning regimen
oxicity occurred in tenpatients. After theuseofmyeloablative
hemotherapy,mucosal toxicity andprolonged cytopenias can
ead to a signiﬁcant risk of infectious complications22; this is14;36(4):264–268 267
the primary cause in 8% of deaths in patients submitted to
aHSCT.23 Pancytopenia although long-lasting is restoredby the
HSC infusion but corresponds to from 5% to 10% of myeloab-
lative regimen-related deaths.24 A study by Mank and Van Der
Lelie25 that assessed infection and mortality, demonstrated
that HSCT is possible without patients being conﬁned to hos-
pital and thus, early hospital discharge is possible. Febrile
neutropenia often lasts for three weeks or more26 and, in this
study it occurred in 58% of the patients before bone marrow
engraftment. This incidence was low when compared to the
97.39% of inpatients reported in one study.27
Some factors may contribute to the increased incidence
of infection, including the use of CVC,28,29 the conditioning
regimen27 and a disruption of the mucocutaneous barrier.29
The incidence of infection is variable, with 57.2% of neu-
tropenic patients presenting with infections of the CVC with
a high prevalence of coagulase-negative staphylococcus.27 In
the neutropenia phase, antimicrobial prophylaxis should be
intensiﬁed so that the incidence of fever can be reduced from
>90% to <60%30; the use of antibiotics from the ﬁrst day after
HSCT shows a reduction in bacterial infection rates and a
reduced need for hospitalization.31 Early discharge is a strat-
egy that can decrease the risk of nosocomial infections due
to the shorter time that the patient is exposed to the hospi-
tal environment.31 In our series, the rate of infection up to
D+30 was 11%; this low rate may be related to early hospital
discharge and the antimicrobial prophylaxis employed.
As already discussed, myeloablative regimens cause
intense pancytopenia which lasts from one to three weeks. In
this period, patientsmust be transfused packed red blood cells
and platelets in an attempt to keep organic functions stable.
In our study, the median time to granulocyte engraftment was
12 days, and platelet engraftment was 15 days, with a median
number of transfusions of three units of red blood cells and
four units of platelet concentrates until outpatient discharge.
Based on these ﬁndings, it is concluded that early hospital
discharge after aHSCT is a safe and feasible treatment strategy
and that the nursing staff plays a key role in the conduct and
management of patients demonstrated by the low occurrence
of complications and rehospitalizations.
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